Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

Ascendis Pharma ( ($ASND) ) has issued an update. On April 8, 2026, Ascendis Pharma reported new Week 52 data from its Phase 2 COACH trial evaluati...

Ascendis Pharma Reports Strong Week 52 COACH Trial Data for TransCon CNP and hGH Combo in Achondroplasia

The latest announcement is out from Ascendis Pharma ( ($ASND) ). On April 8, 2026, Ascendis Pharma announced it will transition from trading Americ...

Ascendis Pharma to Replace ADSs With Direct Ordinary Share Listing on Nasdaq

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND), Encompass Health (EHC) and L...

Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Encompass Health (EHC)

Ascendis Pharma ( ($ASND) ) has shared an update. Ascendis Pharma A/S reported that on March 30, 2026, the exercise window for its outstanding warr...

Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises

Ascendis Pharma ( ($ASND) ) has provided an update. On March 23, 2026, Ascendis Pharma held its Annual General Meeting in Denmark, with 90.16% of o...

Ascendis Pharma Shareholders Back Board, Loss Carryforward and New Buyback Mandate at 2026 AGM

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogent Biosciences (COGT – Research Report) and Asce...

Current Quarter	$0.33	Next Quarter	$0.65
Current Year	$4.35	Next Year	$10.2
QoQ Growth	+97.0%	YoY Growth	+134.5%
3Y EPS CAGR	+0.0%	Target Price	$290.12
Consensus	Buy	Upside	+24.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$232.39	+5.40%	606.93K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$232.39	+5.4%	606.93K
3
4
5
6

ASND

ASND

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel